1-9 of 9
Iris To
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Clinical Trials & Observations
Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Stephen J. Schuster, Sarit E. Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Derrick Kaufman, Antonia Kwan, Elicia Penuel, Christopher R. Bolen, Lihua Elizabeth Budde
Journal: Blood
Blood blood.2024025454.
https://doi.org/10.1182/blood.2024025454
Published: 2024
Includes: Supplemental data
Journal Articles

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Michael L. Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chavez, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Wahib Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 734.
https://doi.org/10.1182/blood-2023-174956
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter's Transformation

Chan Y. Cheah, Sarit Assouline, Ross Baker, Nancy L. Bartlett, Dima El-Sharkawi, Pratyush Giri, Matthew Ku, Stephen J. Schuster, Matthew Matasar, John Radford, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 614.
https://doi.org/10.1182/blood-2023-173796
Published: 2023
Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

L. Elizabeth Budde, Adam J Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Hao Wu, Iris To, Michael C. Wei, Julio C. Chavez
Journal: Blood
Blood (2023) 142 (Supplement 1): 613.
https://doi.org/10.1182/blood-2023-174209
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2023) 142 (Supplement 1): 603.
https://doi.org/10.1182/blood-2023-173692
Published: 2023
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde
Journal: Blood
Blood (2022) 140 (Supplement 1): 1467–1470.
https://doi.org/10.1182/blood-2022-157691
Published: 2022
Journal Articles

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Adam J. Olszewski, L. Elizabeth Budde, Julio Chavez, Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling-Yuh Huw, Song Pham, Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline
Journal: Blood
Blood (2022) 140 (Supplement 1): 3757–3759.
https://doi.org/10.1182/blood-2022-159594
Published: 2022
Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Nancy L. Bartlett, Pratyush Giri, L. Elizabeth Budde, Stephen J. Schuster, Sarit Assouline, Matthew J. Matasar, Sung-Soo Yoon, Miguel Canales, Norma C. Gutierrez, Keith Fay, Chan-Yoon Cheah, Paula Marlton, Volker Wiebking, Shen Yin, Iris To, Chi-Chung Li, Huang Huang, Mingzhu Zhou, Elicia Penuel, Carol O'Hear, Laurie H. Sehn
Journal: Blood
Blood (2021) 138 (Supplement 1): 3573.
https://doi.org/10.1182/blood-2021-147937
Published: 2021
Journal Articles

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Matthew J Matasar, MD, Chan Yoon Cheah, MBBS, Dok Hyun Yoon, Sarit E Assouline, MD MSc, Nancy L. Bartlett, MD, Matthew Ku, Pratyush Giri, Anna Johnston, MBBS (Hons 1), FRACP, FRCPA, Ian W. Flinn, MD PhD, Andre H. Goy, MD, Dimitrios Tzachanis, MD PhD, Carol O'Hear, Shen Yin, Iris To, Kati Sarouei, Chi-Chung Li, Brendan C. Bender, Elicia M. Penuel, Huang Huang, L. Elizabeth Budde
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-135818
Published: 2020